Clinical significance of hepatocyte growth factor/c-Met expression in the assessment of gastric cancer progression

Molecular Medicine Reports

Volumn 11, Issue 5, 2015, Pages 3423-3431

  Noguchi, Eiichiro ^a   Saito, Noboru ^a   Kobayashi, Makio ^a   Kameoka, Shingo ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

C Met; Gastric cancer prognosis; Hepatocyte growth factor; Risk factor

Indexed keywords

SCATTER FACTOR; SCATTER FACTOR RECEPTOR; TUMOR MARKER;

ADULT; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; COHORT ANALYSIS; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; LYMPH VESSEL; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; STOMACH CANCER; TISSUE PREPARATION; AGED; BLOOD; CANCER STAGING; CASE CONTROL STUDY; DISEASE COURSE; GENE EXPRESSION; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; STOMACH TUMOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION; HEPATOCYTE GROWTH FACTOR; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MET; STOMACH NEOPLASMS;

EID: 84922309423     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.3205     Document Type: Article

References (49)

1. Yamada A, Saito N, Kameoka S and Kobayashi M: Clinical significance of epidermal growth factor (EGF) expression in gastric cancer. Hepatogastroenterology 54: 1049-1052, 2007.
2. Hirosawa T, Saito N, Kameoka S and Kobayashi M: Clinical significance of epidermal growth factor (EGF) expression for assessing the spreading of human colon cancer. Nippon Daicho Komonbyo Gakkai Zasshi 55: 402-412, 2002 (In Japanese).
3. Soyama K, Saito N and Kameoka S: Study on adhesion molecule beta1 integrin in colorectal cancer-quantification of blood levels and immunohistological staining. Nippon Daicho Komonbyo Gakkai Zasshi 52: 119-127, 1999 (In Japanese).
4. Saito N, Nishimura H and Kameoka S: Clinical significance of fibronectin expression in colorectal cancer. Mol Med Rep 1: 77-81, 2008.
5. Tani H, Saito N, Kobayashi M and Kameoka S: Clinical significance of keratinocyte growth factor and K-sam gene expression in gastric cancer. Mol Med Rep 7: 1381-1386, 2013.
6. Suda A, Saito N, Seshimo A, Kameoka S and Kobayashi M: Examination of transforming growth factor beta1 expression in the serum and tumor tissue of gastric cancer. Int Surg 94: 182-188, 2009.
7. Daiko W, Saito N and Kameoka S: Clinical significance of TGF-beta1 expression in evaluation of the malignancy of colorectal cancer. Nippon Daicho Komonbyo Gakkai Zasshi 58: 377-382, 2005 (In Japanese).
8. Hashimoto T, Saito N, Kameoka S, Shibata N and Kobayashi M: Clinical significance of hepatocyte growth factor and its specific receptor c-Met expression in colorectal cancer progression. Acta Histochem Cytochem 37: 139-146, 2004.
9. Nakamura T, Nawa K and Ichihara A: Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats. Biochem Biophys Res Commun 122: 1450-1459, 1984.
10. Nakamura T, Teramoto H and Ichihara A: Purification and characterization of a growth factor from rat platelets for mature parenchymal hepatocytes in primary cultures. Proc Natl Acad Sci USA 83: 6489-6493, 1986.
11. Nakamura T, Nawa K, Ichihara A, Kaise N and Nishino T: Purification and subunit structure of hepatocyte growth factor from rat platelets. FEBS Lett 224: 311-316, 1987.
12. Nakamura T, Nishizawa T, Hagiya M, et al: Molecular cloning and expression of human hepatocyte growth factor. Nature 342: 440-443, 1989.
13. Higashio K, Shima N, Goto M, et al: Identity of a tumor cytotoxic factor from human fibroblasts and hepatocyte growth factor. Biochem Biophys Res Commun 170: 397-404, 1990.
14. Stoker M and Gherardi E: Regulation of cell movement: the motogenic cytokines. Biochim Biophys Acta 1072: 81-102, 1991.
15. Nakamura T: Structure and function of hepatocyte growth factor. Prog Growth Factor Res 3: 67-85, 1991.
16. Botraro DP, Rubin JS, Faletro DL, et al: Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 251: 802-804, 1991.
17. Naldini L, Weidner KM, Vigna E, et al: Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor. EMBO J 10: 2867-2878, 1991.
18. Conrotto P, Valdembri D, Corso S, et al: Sema4D induces angiogenesis through Met recruitment by Plexin B1. Blood 105: 4321-4329, 2005.
19. Yi S and Tsao MS: Activation of hepatocyte growth factor-met autocrine loop enhances tumorigenicity in a human lung adenocarcinoma cell line. Neoplasia 2: 226-234, 2000.
20. Schmidt L, Duh FM, Chen F, et al: Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 16: 68-73, 1997.
21. Schmidt L, Junker K, Weirich G, et al: Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene. Cancer Res 58: 1719-1722, 1998.
22. Park WS, Dong SM, Kim SY, et al: Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. Cancer Res 59: 307-310, 1999.
23. Lee JH, Han SU, Cho H, et al: A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene 19: 4947-4953, 2000.
24. Ma PC, Kijima T, Maulik G, et al: c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res 63: 6272-6281, 2003.
25. Ma PC, Jagdeesh S, Jagadeeswaran R, et al: c-MET expression/activation, functions and mutations in non-small cell lung cancer. Proc Am Assoc Cancer Res 44: 1875, 2004.
26. Christensen JG, Burrows J and Salgia R: c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett 225: 1-26, 2005.
27. Nakamura T, Sakai K, Nakamura T and Matsumoto K: Hepatocyte growth factor twenty years on: Much more than a growth factor. J Gastroenterol Hepatol 26: 188-202, 2011.
28. Japanese Gastric Cancer Association: Gastric cancer1. In: Japanese Classification of Gastric Carcinoma. 2nd English Edition. June 1998, pp10-24.
29. Hattori Y, Itoh H, Uchino S, et al: Immunohistochemical detection of K-sam protein in stomach cancer. Clin Cancer Res 2: 1373-1381, 1996.
30. Maeda K, Chung YS, Ogawa Y, et al: Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 77: 858-863, 1996.
31. Nishimoto N: Identification of clinicopathological and molecular prognostic factors in patients of gastric cancer by multivariate analyses. Hiroshima J Med Sci 49: 171-181, 2001 (In Japanese).
32. Wu CW, Chi CW, Su TL, Liu TY, Lui WY and P'eng FK: Serum hepatocyte growth factor level associate with gastric cancer progression. Anticancer Res 18: 3657-3659, 1998.
33. Han SU, Lee JH, Kim WH, Cho YK and Kim MW: Significant correlation between serum level of hepatocyte growth factor and progression of gastric carcinoma. World J Surg 23: 1176-1180, 1999.
34. Taniguchi T, Kitamura M, Arai K, Iwasaki Y, Yamamoto Y, Igari A and Toi M: Increase in the circulating level of hepatocyte growth factor in gastric cancer patients. Br J Cancer 75: 673-677, 1997.
35. Niki M, Okajima K, Isozaki H, et al: Clinical evaluation of preoperative measurement of the serum human hepatocyte growth factor levels in patients of gastric cancer. Jpn J Gastroenterol Surg 28: 2139-2144, 1995 (In Japanese).
36. Ide T, Kitajima Y, Miyoshi A, et al: Tumor-stromal cell interaction under hypoxia increases the invasiveness of pancreatic cancer cells through the hepatocyte growth factor/c-Met pathway. Int J Cancer 119: 2750-2759, 2006.
37. Jiang WG, Martin TA, Parr C, Davies G, Matsumoto K and Nakamura T: Hepatocyte growth factor, its receptor, and their potential value in cancer therapies. Crit Rev Oncol Hematol 53: 35-69, 2005.
38. Catenacci DV, Cervantes G, Yala S, et al: RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma. Cancer Biol Ther 12: 9-46, 2011.
39. Li Y, Chen CQ, He YL, Cai SR, Yang DJ, et al: Abnormal expression of e-cadherin in tumor cells is associated with poor prognosis of gastric carcinoma. J Surg Oncol 106: 304-310, 2012.
40. Taniguchi K, Yonemura Y, Nojima N, et al: The relation between the growth patterns of gastric carcinoma and the expression of hepatocyte growth factor receptor (c-met), autocrine motility factor receptor, and urokinase-type plasminogen activator receptor. Cancer 82: 2112-2122, 1998.
41. Nakajima M, Sawada H, Yamada Y, et al: The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 85: 1894-1902, 1999.
42. Huang TJ, Wang JY, Lin SR, Lian ST and Hsieh JS: Overexpression of the c-met protooncogene in human gastric carcinoma: Correlation to clinical features. Acta Oncol 40: 638-643, 2001.
43. Kubicka S, Claas C, Staab S, et al: p53 mutation pattern and expression of c-erbB2 and c-met in gastric cancer: relation to histological subtypes, Helicobacter pylori infection, and prognosis. Dig Dis Sci 47: 114-121, 2002.
44. Han SU, Lee HY, Lee JH, et al: Modulation of E-cadherin by hepatocyte growth factor induces aggressiveness of gastric carcinoma. Ann Surg 242: 676-683, 2005.
45. Drebber U, Baldus SE, Nolden B, et al: The overexpression of c-met as a prognostic indicator for gastric carcinoma compared to p53 and p21 nuclear accumulation. Oncol Rep 19: 1477-1483, 2008.
46. Zhao J, Zhang X and Xin Y: Up-regulated expression of Ezrin and c-Met proteins are related to the metastasis and prognosis of gastric carcinomas. Histol Histopathol 26: 1111-1120, 2011.
47. Iveson T, Donehower RC, Davidenko I, et al: Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study. Lancet Oncol 15: 1007-1018, 2014.
48. Davidenko I, Iveson T, Donehower RC, et al: Updated efficacy, biomarker, and exposure-response data form a phase 2 study of rilotumumab (R) plus epirubicin, cisplatin, and capecitabine (ECX) in gastric (G) or esophagogastric junction (EGJ) cancer. In: European Society for Medical Oncology Congress. Vienna, 687P, 2012.
49. Yasuhide Yamada: Molecular therapy for gastric cancer. Chin Clin Oncol 2: 5, 2013